Drug Trial Radar · NCT07279298
Effectiveness of Immunization in Preventing Severe Acute Respiratory Infection RSV in Children Under 6 Months in Bogotá
Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,097
Planned (sponsor's estimate)
Start
Jan 1, 2026
Primary completion
Dec 31, 2026
Study completion Jul 31, 2027
Sponsor
- Lead sponsor
- Bogotá District Health SecretariatGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Dec 12, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 day, up to 180 days
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the real-world effectiveness of two preventive immunization strategies against Respiratory Syncytial Virus (RSV)-associated severe acute respiratory infection in infants less than six months of age in Bogotá, Colombia. The strategies include maternal vaccination with RSVpreF administered between 28 and 36 weeks of gestation and neonatal immunization with nirsevimab for infants born to mothers who did not receive RSVpreF during pregnancy. Using a test-negative case-control design embedded in the city's sentinel surveillance system, infants hospitalized for severe respiratory infection will be systematically tested for RSV. Comparative vaccine effectiveness will be estimated to determine the impact of maternal RSV vaccination and neonatal monoclonal antibody immunization on RSV-associated hospitalizations, intensive care admissions, and mortality. The study will generate real-world evidence to inform local and regional public health decisions and guide the implementation of cost-effective hybrid immunization strategies against RSV in middle-income settings.
Conditions
- Respiratory Syncytial Virus Infections
- Severe Acute Respiratory Infection
- Bronchiolitis, Viral
- Viral Respiratory Tract Infection
Interventions
RSVpreF vaccine (Abrysvo) and Nirsevimab (Beyfortus) or unexposedBiological
Maternal vaccination administered between 28 and 36 weeks of gestation and Single-dose monoclonal antibody administered to newborns whose mothers did not receive effective RSVpreF vaccination or unexposed
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hospitalization for RSV-associated Severe Acute Respiratory InfectionTime frame: From birth up to 6 months of age (≤180 days of life)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Secretaria distrital de Salud
Bogotá, Colombia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.